Benefit from convalescent plasma shown in COVID outpatient trial
Researchers have conducted a double-blind, multicentre, randomized, controlled trial, which is known as Convalescent Plasma to Limit SARS-CoV-2 Associated Complications Study to evaluate if early COVID-19 plasma treatment could reduce disease progression and, thereby, reduce hospitalization rate.
United States Drug Administration Early Outpatient Treatment Image Credit Convalescent Plasma Complications Study
Source: news-medical.net